ArticleJournal of medical virology2026
ACE2- and HR2-Mimetic Peptides Inhibit Replication of Two SARS-CoV-2 Variants.
Article in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Several therapeutic approaches to inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) focus on blocking the virus's entry mechanism. This can be blocked in two ways: by interacting with the receptor-binding domain (RBD) of the spike protein and human angiotensin-converting enzyme 2 (ACE2), and by blocking viral-cellular membrane fusion. Here, we designed mimetic peptides based on ACE2 and the region of the viral spike stem. Through in silico molecular docking, we select the peptides with the highest binding energy. The peptides Nat (P-Nat) and 3 (P-3) inhibited RBD-ACE2 interaction in a surrogate ELISA assay by 54% and 58.77%, respectively. On the other hand, P-Nat and P-3 inhibited SARS-CoV-2 in VeroE6 cells, showing 50% inhibitory concentration (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.